U.S. Markets open in 40 hrs, 2 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,288.54 | 73.03 | 0.65% |
| NASDAQ | 2,245.38 | -6.08 | -0.27% |
| S&P 500 | 1,262.90 | 1.38 | 0.11% |
| Day Low 10:21 AM EDT | 8.49 | |
|---|---|---|
| Day High 10:32 AM EDT | 8.74 |
|
| Range | 0.25 | |
| Volume | 171,657 | |
| 30-Day Avg. Vol. | 535,000 |
|
| Difference | -67.91% | |
| Market Cap. | 552.79 M | |
| Change | 1.27 M | |
| Shares Out. | 63.72 M | |
| Percent Traded | 0.27% | |
| Revenue | — | |
| Earnings | — | |
| EPS (TTM) | -1.442 |
| 52-Wk Low 2/7/08 | 5.78 | |
|---|---|---|
| 52-Wk High 11/6/07 | 12.62 |
|
| Range | 6.84 | |
| Prev. Close 7/2/08 | 8.65 | |
| Today's Open | 8.64 | |
| Change | -0.12% | |
| Dividend (TTM) | — | |
| Div. Yield (TTM) | — |
|
| Beta | 2.2905 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | -11.00 |
Cardiome has a heart for those with cardiovascular ailments. The company is developing new therapies for atrial arrhythmia and other heart conditions. Cardiome's lead drug candidate is vernakalant hydrochloride, ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.287 12/31/07 | -0.40 12/31/07 |
-0.113
Missed
|
| Last Quarter | -0.221 3/31/08 | -0.35 3/31/08 |
-0.129
Missed
|
| Quarterly - | Annual - | |
|---|---|---|
| Total Revenue | — | — |
| Gross Profit | — | — |
| Operating Income | — | — |
| Net Income | — | — |
